Skip to Content

'
Christopher G. Wood, M.D., F.A.C.S.

Present Title & Affiliation

Primary Appointment

Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Deputy Chairman, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1989 Northwestern University Medical School, Chicago, IL, MD, Medicine
1985 Purdue University, West Lafayette, IN, BS, Honors Degree, Molecular Biology

Postgraduate Training

1995-1998 Clinical Fellowship, Urologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
1991-1995 Clinical Residency, Urology, Northwestern Memorial Hospital/McGaw Medical Center, Chicago, IL
1989-1991 Clinical Residency, General Surgery, Northwestern Memorial Hospital/McGaw Medical Center, Chicago, IL

Board Certifications

2/2000 American Board of Urology

Experience/Service

Academic Appointments

Associate Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004-2010
Associate Professor, Department of Cancer Biology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2004-2009
Assistant Professor, Department of Urology, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1998-2004
Assistant Professor, Department of Cancer Biology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1998-2004

Other Appointments/Responsibilities

Renal Cancer Task Force Committee Member, National Cancer Institute, Bethesda, MD, 5/2010-present
Member - AUA Practice Guidelines Panel - Kidney, American Urological Association, Linthicum, MD, 6/2009-present

Honors and Awards

2011-2012 Best Doctors in America
2009-2010 Best Doctors in America
2007-2008 Best Doctors in America
2006-2007 Best Doctors in America
2006-2007 Who's Who in Medicine and Healthcare, Marquis
2005-2006 Best Doctors in America
2004 Top Doctors in Houston, H Texas Magazine
2003 Guide to America's Top Physicians
1998 CapCURE Young Investigator Award
1995 American Foundation For Urologic Disease Research Scholarship (Pfizer Scholar

Selected Publications

Peer-Reviewed Original Research Articles

1. Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Zigeuner R, Weizer A, Sagalowsky A, Bensalah K, Raman JD, Bolenz C, Kassou W, Koppie TM, Wood CG, Wheat J, Langner C, Ng CK, Capitanio U, Bertini R, Fernández MI, Mikami S, Isida M, Ströbel P, Montorsi F. The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur Urol 56(3):512-8, 9/2009. e-Pub 6/2009. PMID: 19559518.
2. Capitanio U, Shariat SF, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Raman JD, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Fernández MI, Ströbel P, Wheat J, Zigeuner R, Langner C, Waldert M, Oya M, Guo CC, Ng C, Montorsi F, Wood CG, Margulis V, Karakiewicz PI. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol 56(1):1-9, 7/2009. e-Pub 4/2009. PMID: 19361911.
3. Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, Patard JJ, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Ströbel P, Fernández M, Karakiewcz P, Shariat SF. Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy. Eur Urol, 7/2009. e-Pub 7/2009. PMID: 19619934.
4. Vikram R, Ng CS, Tamboli P, Tannir NM, Jonasch E, Matin SF, Wood CG, Sandler CM. Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. Radiographics 29(3):741-54, May-Jun, 5/2009. PMID: 19448113.
5. Clague J, Lin J, Cassidy A, Matin S, Tannir NM, Tamboli P, Wood CG, Wu X. Family History and Risk of Renal Cell Carcinoma: Results from a Case-Control Study and Systematic Meta-Analysis. Cancer Epidemiol Biomarkers Prev 118(3):801-7, 2/2009. PMID: 19240244.
6. Kassouf W, Siemens R, Morash C, Lacombe L, Jewett M, Goldenberg L, Chin J, Chetner M, Wood CG, Tanguay S, Aprikian AG. Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma. Can Urol Assoc J 3(1):73-6, 2/2009. PMCID: PMC2645874.
7. Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, Lotan Y, Remzi M, Bolenz C, Langner C, Weizer A, Montorsi F, Bensalah K, Koppie TM, Fernández MI, Raman JD, Kassouf W, Wood CG, Suardi N, Oya M, Shariat SF. Lymphovascular Invasion Predicts Clinical Outcomes in Patients With Node-Negative Upper Tract Urothelial Carcinoma. J Clin Oncol 27(4):612-8, 2/2009. PMID: 19075275.
8. Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Bensalah K, Ng CK, Raman JD, Kikuchi E, Montorsi F, Oya M, Wood CG, Fernandez M, Evans CP, Koppie TM. Adjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: Results From the Upper Tract Urothelial Carcinoma Collaboration. J Urol 182(3):900-6, Sep, 2009. PMID: 19616245.
9. Kim J, Jonasch E, Alexander A, Short JD, Cai S, Wen S, Tsavachidou D, Tamboli P, Czerniak BA, Do KA, Wu KJ, Marlow LA, Wood CG, Copland JA, Walker CL. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 15(1):81-90, 2009. PMID: 19118035.
10. Fernández MI, Shariat SF, Margulis V, Bolenz C, Montorsi F, Suardi N, Remzi M, Wood CG, Roscigno M, Kikuchi E, Oya M, Zigeuner R, Langner C, Weizer A, Lotan Y, Koppie TM, Raman JD, Karakiewizc P, Bensalah K, Schultz M, Bernier P. Evidence-based Sex-related Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results of Large Multicenter Study. Urology 73(1):142-6, Jan, 2009. PMID: 18845322.
11. Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Langner C, Lotan Y, Weizer A, Bensalah K, Raman JD, Bolenz C, Guo CC, Wood CG, Zigeuner R, Wheat J, Kabbani W, Koppie TM, Ng CK, Suardi N, Bertini R, Fernández MI, Mikami S, Isida M, Michel MS, Montorsi F. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 181(6):2482-9, Jun, 2009. PMID: 19371878.
12. Marguls V, Wood CG. Is patient performance status always an accurate surrogate for predicting tumor biology in patients with metastatic renal cell carcinoma. Cancer 113(6):1282-3, Sep, 2009.
13. Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer 115(6):1310-7, Mar, 2009. PMID: 19156903.
14. Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, Thall PF, Wen S, Horne E, Oborn CJ, Langley R, Fidler IJ, Pettaway CA. Neoadjuvant Platelet Derived Growth Factor Receptor Inhibitor Therapy Combined With Docetaxel and Androgen Ablation for High Risk Localized Prostate Cancer. J Urol 181(1):81-7, Jan, 2009. PMID: 19012911.
15. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG, Wood CG. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115(6):1224-33, Mar, 2009. PMID: 19156917.
16. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol 27(25):4076-81, Sep, 2009. PMID: 19636008.
17. Margulis V, McDonald M, Tamboli P, Swanson DA, Wood CG. Predictors of Oncological Outcome After Resection of Locally Recurrent Renal Cell Carcinoma. J Urol 181(5):2044-51, May, 2009. PMID: 19286220.
18. Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int 104(4):456-60, Aug, 2009. PMID: 19338544.
19. Bolenz C, Shariat SF, Fernández MI, Margulis V, Lotan Y, Karakiewicz P, Remzi M, Kikuchi E, Zigeuner R, Weizer A, Montorsi F, Bensalah K, Wood CG, Roscigno M, Langner C, Koppie TM, Raman JD, Mikami S, Michel MS, Ströbel P. Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. BJU Int 103(3):302-6, Feb, 2009. PMID: 18990164.
20. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and Vitamin E: Cell Type- and Intervention-Specific Tissue Effects in Prostate Cancer. J Natl Cancer Inst 101(5):306-20, Mar, 2009. PMID: 19244175.
21. Clague J, Shao L, Lin J, Chang S, Zhu Y, Wang W, Wood CG, Wu X. Sensitivity to NNKOAc is associated with renal cancer risk. Carcinogenesis 30(4):706-10, Apr, 2009. PMID: 19237609.
22. Remzi M, Haitel A, Margulis V, Karakiewizc P, Montorsi F, Kikuchi E, Zigeuner R, Weizer A, Bolenz C, Bensalah K, Suardi N, Raman JD, Lotan Y, Waldert M, Ng CK, Fernández M, Koppie TM, Ströbel P, Kabbani W, Murai M, Langner C, Roscigno M, Wheat J, Guo CC, Wood CG, Shariat SF. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int 103(3):307-11, Aug, 2009. PMID: 18990163.
23. Horikawa Y, Wood CG, Yang H, Zhao H, Ye Y, Gu J, Lin J, Habuchi T, Wu X. Single Nucleotide Polymorphisms of microRNA Machinery Genes Modify the Risk of Renal Cell Carcinoma. Clin Cancer Res 14(23):7956-62, 12/2008. PMID: 19047128.
24. Wood CG. A vaccine for renal cancer. Lancet 372(9648):1460-1, 10/2008.
25. Oflazoglu E, Stone IJ, Gordon K, Wood CG, Repasky EA, Grewal IS, Law CL, Gerber HP. Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker. Clin Cancer Res 14(19):6171-80, 10/2008. PMID: 18809969.
26. Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG. Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma. Urology 73(2):337-41, 10/2008. PMID: 18950837.
27. Ng CS, Wood CG, Silverman PM, Tannir NM, Tamboli P, Sandler CM. Renal cell carcinoma: diagnosis, staging, and surveillance. AJR Am J Roentgenol 191(4):1220-32, 10/2008. PMID: 18806169.
28. Margulis V, Wood CG. Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy? Eur Urol 54(3):489-92, 9/2008. PMID: 18206292.
29. Margulis V, Lin J, Yang H, Wang W, Wood CG, Wu X. Genetic susceptibility to renal cell carcinoma: the role of DNA double-strand break repair pathway. Cancer Epidemiol Biomarkers Prev 17(9):2366-73, 9/2008. PMID: 18768505.
30. Jain R, Mathew P, Wood CG, Tannir NM. Sunitinib-induced acute hemolysis without hypertension: a case report. Clin Genitourin Cancer 6(2):122-3, 9/2008. PMID: 18824436.
31. Margulis V, Maity T, Zhang XY, Cooper SJ, Copland JA, Wood CG. Type III Transforming Growth Factor-{beta} (TGF-{beta}) Receptor Mediates Apoptosis in Renal Cell Carcinoma Independent of the Canonical TGF-{beta} Signaling Pathway. Clin Cancer Res 14(18):5722-30, 9/2008. PMID: 18794080.
32. Xing J, Chen M, Wood CG, Lin J, Spitz MR, Ma J, Amos CI, Shields PG, Benowitz NL, Gu J, de Andrade M, Swan GE, Wu X. Mitochondrial DNA Content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst 100(5):1104-12, 8/2008. PMID: 18664653.
33. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 180(3). e-Pub 7/2008. PMID: 18635226.
34. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, Isakov L, Flanigan R, Figlin R, Gupta R, Escudier B, Escudier B. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372(9633):145-54, 7/2008. PMID: 18602688.
35. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180(1):94-8, 7/2008. PMID: 18485389.
36. Zhu Y, Horikawa Y, Yang H, Wood CG, Habuchi T, Wu X. BPDE induced lymphocytic chromosome 3p deletions may predict renal cell carcinoma risk. J Urol 179(6):2416-21, 6/2008. PMID: 18433782.
37. Margulis V, Wood CG, Jonasch E, Matin SF. Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. Curr Oncol Rep 10(3):253-8, 5/2008. PMID: 18765156.
38. Hempel N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG, Blobe GC. Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta. Carcinogenesis 29(5):905-12, 5/2008. PMID: 18299279.
39. Margulis V, tamboli P, Matin SF, Swanson DA, Wood CG. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer 112(7):1480-1488, 4/2008.
40. Wood CG. Local recurrence after primary therapy for clinically localized prostate cancer: is radiation or surgery "Better" in the salvage setting? J Surg Oncol 97(5):376, 4/2008.
41. Doria C, Fischer CP, Wood CG, Li PM, Marra S, Hart J. Phase III, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin 24(3):785-94, 3/2008. PMID: 18241525.
42. Booth J, Matin SF, Ahrar K, Tamboli P, Wood CG. Contemporary strategies for treating nonhereditary synchronous bilateral renal tumors and the impact of minimally invasive, nephron-sparing techniques. Urol Oncol 26(1):37-42, Jan-Feb, 1/2008. PMID: 18190828.
43. Lin J, Pu X, Wang W, Matin S, Tannir NM, Wood CG, Wu X. Case-Control Analysis of Nucleotide Excision Repair Pathway and the Risk of Renal Cell Carcinoma. Carcinogenesis 113(6):1282-3, Sep, 2008. PMID: 18711149.
44. Matin SF, Ahrar K, Wood CG, Daniels M, Jonasch E. Patterns of intervention for renal lesions in von Hippel-Lindau disease. BJU Int 102(8):940-5, Sep, 2008.
45. Davis JW, Chang DW, Chevray P, Wang R, Shen Y, Wen S, Pettaway CA, Pisters LL, Swanson DA, Madsen LT, Huber N, Troncoso P, Babaian RJ, Wood CG. Randomized Phase II Trial Evaluation of Erectile Function after Attempted Unilateral Cavernous Nerve-Sparing Retropubic Radical Prostatectomy with versus without Unilateral Sural Nerve Grafting for Clinically Localized Prostate Cancer. Eur Urol 55(5):1135-43, May, 2008. PMID: 18783876.
46. Margulis V, Tamboli P, Jacobsohn KM, Swanson DA, Wood CG. Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma. BJU Int 100(6):1235-9, 12/2007. PMID: 17979923.
47. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Surgical morbidity associated with administration of targeted molecular therapies prior to cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 100(6):1235-9, 12/2007.
48. Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer 110(12):2700-8, 12/2007. PMID: 17948916.
49. Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin SF, Swanson DA, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol 178(5):1896-900, 11/2007.
50. Margulis V, Tamboli P, Matin SF, Meisner M, Swanson DA, Wood CG. Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. J Urol 178(5):1878-82, 11/2007.
51. Shao L, Wood CG, Zhang D, Tannir NM, Matin S, Dinney CP, Wu X. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol 178(4 Pt 1):1492-6, 10/2007. PMID: 17707063.
52. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, Sun LZ, Ahlquist DA, Wood CG, Copland JA. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 13(16):4740-9, 8/2007.
53. Lin X, Wood CG, Shao L, Huang M, Yang H, Dinney CP, Wu X. Risk assessment of renal cell carcinoma using alkaline comet assay. Cancer 110(2):282-8, 7/2007. PMID: 17549681.
54. Gannon CJ, Zager JS, Chang GJ, Feig BW, Wood CG, Skibber JM, Rodriguez-Bigas MA. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Annals of Surg Onc 14(6):1870-7, 6/2007.
55. Margulis V, Sánchez-Ortiz RF, Tamboli P, Cohen DD, Swanson DA, Wood CG. Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management. Cancer 109(10):2025-30, 5/2007. PMID: 17420980.
56. Kader AK, Tamboli P, Luongo T, Matin SF, Bell K, Jonasch E, Swanson DA, Wood CG. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol 177(3):855-60; discussion 860-1, 3/2007. PMID: 17296358.
57. Black PC, Basen-Engquist K, Wang X, Swartz RJ, Eddingst T, Matin SF, Swanson D, Wood CG, Pisters LL, Babaian RJ, Troncoso P, Pettaway CA. A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial. BJU Int 100(1):63-9., 2007.
58. Kassouf W, Sanchez-Ortiz R, Tamboli P, Jonasch E, Merchant MM, Spiess PE, Wood CG. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: The M.D. Anderson Cancer Center experience. Urology 69(5)(5):835-8, 2007. PMID: 17482917.
59. Jacobsohn KM, Ahrar K, Wood CG, Matin SF. Is radiofrequency ablation safe for solitary kidneys? Urology 69(5):819-23; discussion 823., 2007.
60. Margulis V, Tamboli P, Matin SF, Meissner M, Swanson DA, Wood CG. Redefining pT3 renal cell carcinoma in the modern era: a proposal for a revision of the current TNM primary tumor classification system. Cancer 109(12):2439-44, 2007.
61. Lin X, Wood CG, Shao L, Huang M, Yang H, Dinney CP, Wu X. Risk assessment of renal cell carcinoma using alkaline-comet assay. Cancer 110(2):282-8, 2007.
62. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int 98(6):1176-80, 12/2006. PMID: 17125474.
63. Matin SF, Dhanani N, Acosta M, Wood CG. Conventional and hand-assisted laparoscopic radical nephrectomy: Comparative analysis of 271 cases. J Endourol 11:891-4, 11/2006. PMID: 17144857.
64. Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M, Pettaway CA, Dinney CP, Pisters LL. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol 176(4 Pt 1):1463-7, 10/2006. PMID: 16952661.
65. Matin SF, Madsen LT, Wood CG. Laparoscopic cytoreductive nephrectomy: the M. D. Anderson Cancer Center experience. Urology 68(3):528-32, 9/2006. PMID: 16979706.
66. Westney OL, Scott S, Wood C, Eddings T, Johnson MM, Taylor JM, McGuire E, Pisters LL. Suburethral sling at the time of radical prostatectomy in patients at high risk of postoperative incontinence. BJU Int 98(2):308-13, 8/2006. PMID: 16879670.
67. Canfield SE, Kamat AM, Sanchez-Ortiz RF, Detry M, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 175(3 Pt 1):864-9, 3/2006. PMID: 16469567.
68. Law CL, Godon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, Petroziello JM, Ryan MC, Smith L, Simon R, Sauter G, Oflazoglu E, Doronina SO, Meyer DL, Francisco JA, Carter P, Senter PD, Copland JA, Wood CG, Wahl AF. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 66(4):2328-37, 2/2006.
69. Wood CG. Molecular markers of prognosis in renal cell carcinoma: Insight into tumor biology helps define risk and provides targets for therapy. J Surg Oncol 94(4):264-5, 2006.
70. Bartholomeusz C, Itamochi H, Yuan LX, Esteva FJ, Wood CG, Terakawa N, Hung MC, Ueno NT. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res 65(18):8406-13, 9/2005. PMID: 16166319.
71. Kim J, Sun P, Lam YW, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, McDonnell TJ, Lieberman R, Logothetis C, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev 14(7):1697-702, 7/2005. PMID: 16030104.
72. Cohen DD, Matin SF, Steinberg JR, Zagone R, Wood CG. Evaluation of the intact specimen after laparoscopic radical nephrectomy for clinically localized renal cell carcinoma identifies a subset of patients at increased risk for recurrence. J Urol 173(5):1487-90; discussion 1490-1, 5/2005. PMID: 15821465.
73. Ahrar K, Matin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, Rao S, Tannir NM, Jonasch E, Pisters LL, Rozner MA, Kennamer DL, Hicks ME. Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. J Vasc Interv Radiol 16(5):679-88, 5/2005. PMID: 15872323.
74. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guille F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 23(12):2763-71, 4/2005. PMID: 15837991.
75. Wyatt RB, Sanchez-Ortiz RF, Wood CG, Ramirez E, Logothetis C, Pettaway CA. Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer. J Natl Med Assoc 96(12):1587-93, 12/2004. PMID: 15622688.
76. Sanchez-Ortiz RF, Madsen LT, Bermejo CE, Wen S, Shen Y, Swanson DA, Wood CG. A renal mass in the setting of a nonrenal malignancy: When is a renal tumor biopsy appropriate? Cancer 101:2195-201, 11/2004. PMID: 15470708.
77. Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han KR, Cindolo L, De La Taille A, Tostain J, Artibani W, Dinney CP, Wood CG, Swanson DA, Abbou CC, Lobel B, Mulders PF, Chopin DK, Figlin RA, Belldegrun AS. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 22(16):3316-22, 8/2004. PMID: 15310775.
78. Sanchez-Ortiz RF, Rosser CJ, Madsen LT, Swanson DA, Wood CG. Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma. J Urol 171(6 Pt 1):2160-5, 6/2004. PMID: 15126777.
79. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, Do KA, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto C, Jacobson MG, Parker K, Merritt JA, Steiner MS, Logothetis CJ. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 10(8):2587-93, 4/2004. PMID: 15102659.
80. Arap MA, Lahdenranta J, Hajitou A, Marini FC, 3rd, Wood CG, Wright KC, Fueyo J, Arap W, Pasqualini R. Model of unidirectional transluminal gene transfer. Mol Ther 9(2):305-10, 2/2004. PMID: 14759814.
81. Sanchez-Ortiz R, Madsen LT, Swanson DA, Canfield SE, Wood CG. Closed suction or penrose drainage after partial nephrectomy: does it matter? J Urol 171(1):244-6, 2004. PMID: 14665885.
82. Han KR, Bleumer I, Pantuck AJ, Kim HL, Dorey FJ, Janzen NK, Zisman A, Dinney CP, Wood CG, Swanson DA, Said JW, Figlin RA, Mulders PF, Belldegrun AS. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol 170(6 Pt 1):2221-4, 12/2003. PMID: 14634383.
83. Copland JA, Luxon BA, Ajani L, Maity T, Campagnaro E, Guo H, LeGrand SN, Tamboli P, Wood CG. Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. Oncogene 22:6109-6118, 9/2003. PMID: 12970754.
84. Sweeney P, Wood CG, Pisters LL, Slaton JW, Vaporciyan A, Munsell M, Carpenter S, Putnam J, Swisher SG, Walsh G, Swanson D, Dinney CP. Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol 21(5):327-33, 9/2003. PMID: 14670538.
85. Sanchez-Ortiz RF, Tannir N, Ahrar K, Wood CG. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine? J Urol 170(1):178-9, 7/2003. PMID: 12796677.
86. Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, Grossman HB, Dinney CP, Swanson DA, Pisters LL. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 169(6):2113-7, 6/2003. PMID: 12771730.
87. Copland JA, Davies PJ, Shipley GL, Wood CG, Luxon BA, Urban RJ. The use of DNA microarrays to assess clinical samples: the transition from bedside to bench to bedside. Recent Prog Horm Res 58:25-53, 5/2003. PMID: 12795413.
88. Sexton WJ, Wood CG, Kim R, Pisters LL. Repeat retroperitoneal lymph node dissection for metastatic testis cancer. J Urol 169(4):1353-6, 4/2003. PMID: 12629359.
89. Ardelt PU, Wood CG, Chen L, Mintz PJ, Moya C, Arap MA, Wright KC, Pasqualini R, Arap W. Targeting urothelium: ex vivo assay standardization and selection of internalizing ligands. J Urol 169(4):1535-40, 4/2003. PMID: 12629410.
90. Chang DW, Wood CG, Kroll SS, Youssef AA, Babaian RJ. Cavernous nerve reconstruction to preserve erectile function following non-nerve-sparing radical retropubic prostatectomy: a prospective study. Plast Reconstr Surg 111(3):1174-81, 3/2003. PMID: 12621188.
91. Evans CP, Tunuguntla HS, Saffarian AR, Wood CG. Does retroperitoneal lymphadenectomy for testicular germ cell tumor require a different approach in the presence of horseshoe kidney? J Urol 169(2):503-6, 2/2003. PMID: 12544297.
92. Wood CG, Chang D, Kroll S, Babaian RJ. Sural nerve grafting to the cavernosal nerve stumps following bilateral non-nerve sparing radical prostatectomy significantly enhances spontaneous erectile activity and sexual activity. Prost Ca Prost Dis 5 (Suppl 1):S35A, 8/2002.
93. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 61(14):5652-9, 7/2001. PMID: 11454720.
94. Walls R, Thibault A, Liu L, Wood C, Kozlowski JM, Figg WD, Sampson ML, Elin RJ, Samid D. The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. Prostate 29(3):177-82, 9/1996.

Invited Articles

1. Chiong E, Wood CG, Margulis V. Role of cytoreductive nephrectomy in renal cell carcinoma. Future Oncol 5(6):859-69, 8/2009. PMID: 19663735.
2. Wood CG, Mulders P. Vitespen: a preclinical and clinical review. Future Oncol 5(6):763-74, 8/2009. PMID: 19663726.
3. Culp SH, Wood CG. Words of wisdom. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo- controlled phase III trial. Eur Urol 55(6):1484-5, 6/2009. PMID: 19650216.
4. Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer 115(10 Suppl):2247-51, 5/2009. PMID: 19402064.
5. Wood CG, Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 115(10 Suppl):2355-60, 5/2009. PMID: 19402066.
6. Abel EJ, Wood CG. Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol 6(7):375-83, July, 2009. PMID: 19528960.
7. Delacroix SE, Wood CG. The role of lymphadenectomy in renal cell carcinoma. Curr Opin Urol 19(5):465-472, 2009. PMID: 19571759.
8. Margulis V, Matin SF, Wood CG. Cytoreductive nephrectomy in metastatic renal cell carcinoma. Curr Opin Urol 18(5):474-80, 9/2008.
9. Margulis V, Wood CG. The Role of Lymph Node Dissection in Renal Cell Carcinoma: The Pendulum Swings Back. Cancer J 14(5):308-14, Sep-Oct, 9/2008. PMID: 18836335.
10. Wood CG. Adjuvant approaches to renal cell carcinoma. Clinical Advances Hemat Oncology 6(1):19-21, 1/2008.
11. Margulis V, Wood CG. Pre-surgical targeted molecular therapy in renal cell carcinoma. BJU Int 103(2):150-3, Jan, 2008. PMID: 19007359.
12. Margulis V, Wood CG. Update on staging controversies for locally advanced renal cell carcinoma. Expert Rev Anticancer Ther 7(7):909-14, 7/2007.
13. Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG Jr, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Ca Res 13(2 Pt2):667s-670s. Review., 2007.
14. Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma. Clin Ca Res 13(2 Pt 2):697s-702s, 2007.
15. Wood CG. Reconstructing the cytoreductive paradigm: why timing of nephrectomy is key in era of targeted therapy. Kidney Ca Journal (5)2:52-56, 2007.
16. Jacobsohn KM, Ahrar K, Wood CG, Matin SF. Reply. Urology 69(5):823, 2007.
17. Halbert R, Figlin RA, Atkins M, Bernal M, Hutson TE, Bukowski RM, Khan KD, Motzer RJ, Wood CG, Geerhart BL, Dubois R. Treatment of patients with metastatic renal cell carncer: a RAND appropriateness panel. Cancer 107(10):2375-2383, 11/2006.
18. Howard GE, Wood CG. Staging refinements in renal cell carcinoma. Curr Opin Urol 16(5):317-20, 9/2006. PMID: 16905974.
19. Wood CG. Adjuvant RCC therapy remain s elusive: vaccines, monoclonal antibody therapy, and tyrosine kinase inhibotirs all have potential. Renal and Urology News 5(5):20-21, 2006.
20. Jacobsohn KM, Wood CG. Adjuvant therapy for renal cell carcinoma. Semin Oncol 33(5):576-82. Review, 2006.
21. Russo P, Wood CG. Radical nephrectomy for kidney cancer is a risk factor for chronic kidney disease. Oncology Times 28(20):20-24, 2006.
22. Wood CG. Adjuvant Therapy for RCC. Clin Adv Hemat and Onc 3(6):S3, 3-5, 8/2005.
23. Wood CG. The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol Clin North Am 30(3):581-8, 8/2003. PMID: 12953756.
24. Copland JA, Davies PJ, Shipley GL, Wood CG, Luxon BA, Urban RJ. The use of DNA microarrays to assess clinical samples: The transition from bedside to bench to bedside. Recent Prog Horm Res 58:25-53, 2003.
25. Wood CG. The role of chemoprotectants in cancer supportive care: testicular cancer. Oncology Spectrum 2(8):574-575, 12/2001.
26. Wood CG. Tumour angiogenesis as a target for adenoviral mediated antisense gene therapy in human prostate cancer. Prostate Cancer Prostatic Dis 3(S1):S43, 12/2000. PMID: 12497151.
27. Liebert M, Gebhardt D, Wood C, Chen IL, Ellard J, Amancio D, Grossman HB. Urothelial differentiation in bladder cancer. Adv Exp Med Biol 462:437-448, 1999.
28. Wood CG, von Eschenbach AC. An agenda for prostate cancer research. AUA News 2(2):29-30, 3/1997.

Book Chapters

1. Kader AK, Wood CG. Adjuvant Therapy for Renal Cell Carcinoma: Targeted Approaches. In: Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Second. Ed(s) RM Bukowski, RA Figlin, RJ Motzer. The Human Press: New York, NY, 473-495, 2009.
2. Margulis V, Wood CG. Surgical Management of Locally Advanced Renal Cell Carcinoma. In: Renal Cell Carcinoma. Ed(s) Rini B, Campbell S. BC Decker: Shelton, Connecticut, 130-139, 2009.
3. Jonasch E, Wood CG, Atkins MB. Renal Neoplasia. In: The Kidney. 2, 8th Edition. Ed(s) BM Brenner. Saunders Elsevier: Philadelphia, PA, 1350-1369, 2008.
4. Margulis V, Wood CG. Renal Cell Carcinoma: Overview, Diagnosis and Surgical Treatment. In: New Treatment Paradigms in Renal Cell Cancer, CME 3. Ed(s) Bukowski R. CMP Medica: Cleveland, Ohio, 1-17, 2007.
5. Wood CG. Retroperitoneal Lymph Node Dissection for Testicular Cancer. In: Operative Techniques In General Surgery. 8(2). Ed(s) Koltun WA, Gershenwald J. Elsevier: MASS, 112-116, 2007.
6. Carroll PR, Altwein J, Brawley O, Cockett A, Cooperberg M, Hirao Y, Lobel B, McLeod D, Neal D, Van Poppel H, Richard F, Scher H, Wood C,. Management of Dessiminated Prostate Cancer. In: Prostate Cancer, 2003. Ed(s) L Denis, G bartsch, S Khoury, M Murai, A Partin. Health Publications: France, 249-284, 2003.
7. Wood CG, von Eschenbach AC. The Clinical Problem of Prostate Cancer. In: Progress in Anti-Cancer Chemotherapy. Ed(s) D Khayat, GN Hortobagyi. Springer-Verlag: France, 203-211, 2000.

Last updated: 8/9/2013